DYN

Dyne Therapeutics, Inc. is a clinical-stage neuromuscular disease company. It is discovering and advancing therapeutics for people living with genetically driven neuromuscular diseases. Leveraging the modularity of its FORCE platform, it is developing targeted therapeutics that deliver to muscle and the central nervous system (CNS). It has a broad pipeline for neuromuscular diseases, including clinical programs for myotonic dystrophy type 1 (DM1) and Duchenne muscular dystrophy (DMD) and preclinical programs for facioscapulohumeral muscular dystrophy (FSHD) and Pompe disease. Its product candidate, DYNE-101, is being evaluated in ACHIEVE, an ongoing Phase I/II global clinical trial in patients with DM1. Its product candidate, DYNE-251, is being evaluated in DELIVER, an ongoing Phase I/II global clinical trial in patients with DMD who have mutations amenable to exon 51 skipping. Its other product candidates are DYNE-302 and DYNE-401. DYNE-302 addresses the genetic basis of FSHD.

Wall Street analysts forecast DYN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DYN is 33.50 USD with a low forecast of 11.00 USD and a high forecast of 48.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Dyne Therapeutics Inc revenue for the last quarter amounts to -113.89M USD, increased 7.79 % YoY.

Dyne Therapeutics Inc. EPS for the last quarter amounts to -109964000.00 USD, increased 46.85 % YoY.

Dyne Therapeutics Inc (DYN) has 191 emplpoyees as of December 16 2025.

Today DYN has the market capitalization of 3.17B USD.